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Introduction
Skp2 is the limiting component of the E3 ligase controlling 
the proteosomal degradation of p27
kip1 (p27) in late G1/S 
phase (Carrano et al., 1999; Tsvetkov et al., 1999). Skp2 can 
also stimulate p27 degradation and S phase entry in serum-
deprived cells (Sutterluty et al., 1999). Although Skp2 has sev-
eral other substrates (Reed, 2003), the importance of p27 as 
a Skp2 substrate is emphasized by the fi  nding that Skp2-p27 
double-null mice lose most of the Skp2 knock out phenotype 
(Nakayama and Nakayama, 2005). It was therefore surprising 
that knockin mouse embryo fi  broblasts (MEFs) expressing 
p27
T187A, a Skp2-resistant p27 mutant, did not show a pro-
nounced defect in mitogen-stimulated S phase entry (Malek 
et al., 2001).
Skp2 levels are inhibited posttranscriptionally by retino-
blastoma protein (Rb) through its effects on anaphase-promoting 
complex/cyclosome and its activator Cdh1 (APC/C
Cdh1)–mediated 
Skp2 degradation (Hsu et al., 2002; Bashir et al., 2004; Ji et al., 
2004; Wei et al., 2004; Binne et al., 2007). In this report, we 
describe a parallel regulation of Skp2 by Rb that results in the 
formation of a transcriptionally based Skp2 autoinduction loop. 
Interference with this loop selectively affects the transition to 
mitogen-independent cell cycle progression, also called the 
 restriction  point.
Results and discussion
A conserved E2F site links Skp2 regulation 
to Rb activation/inactivation
Transcript profi  ling indicates that E2F controls Skp2 gene ex-
pression (Markey et al., 2002; Vernell et al., 2003), and we found, 
in agreement with this data, that ectopic expression of human 
papilloma virus–E7 (E7), which inactivates pocket proteins and 
releases E2Fs, rescued Skp2 mRNA and protein expression in 
serum-starved MEFs (Fig. 1 A). We used zPicture (available at 
http://zpicture.dcode.org/) to identify conserved domains in the 
mouse versus the human, chimp, and dog Skp2 promoters, and 
rVista (available at http://rvista.dcode.org/) to look for putative 
E2F binding sites within the conserved domains. This analysis 
(Fig. 1 B) revealed an evolutionarily conserved E2F binding site 
in human, chimp, and dog Skp2 promoters that matches the E2F 
consensus (SCGSSAAA; Tao et al., 1997). The homologous 
mouse sequence (GCGCTAAA) differs from the consensus by 
one base (Fig. 1 B), but this same sequence acts as a functional 
E2F site in the E2F1 promoter (Neuman et al., 1994). The mouse 
sequence begins at position +114 relative to the transcription 
start site, between the transcription and translation start sites. 
It is the only E2F site we could identify in the mouse Skp2 
  promoter. Imaki et al. (2003) have reported that the Skp2 pro-
moter contains a binding site for the transcription factor GABP. 
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Figure 1.  A conserved E2F site in the Skp2 promoter. (A) Vector- (V) or E7- (E7) transfected MEFs were incubated in 10% FCS or serum starved. Skp2 
mRNA levels were determined by QPCR and plotted relative to the levels observed in the vector-transfected cells incubated with 10% FCS. A dupli-
cate experiment was Western blotted for Skp2 and Cdk4 (loading control). (B) The conserved E2F site on the mouse, human, chimp, and dog Skp2 
promoters. The numbers shown are relative to the known or putative transcription start sites. (C) MEFs transfected with the wild-type Skp2 promoter– (S
wt) 
or E2F-mutated Skp2 promoter– (S
Em) luciferase constructs were analyzed by ChIP using anti-E2F1 (E) or preimmune IgG (I). (D) Skp2 promoter activity in 
serum-stimulated MEFs expressing S
wt or S
Em promoter–luciferase constructs and either empty vector or E7. After 24 h in 10% FCS, Skp2 promoter–
  luciferase activity was plotted relative to the activity of the wild-type Skp2 promoter transfected with empty vector. (E–H) Serum-starved MEFs were 
stimulated with 10% FCS. (E) The levels of Skp2 and cyclin E1 mRNAs were determined by QPCR and plotted relative to the level of cyclin E mRNA 
in the starved cells. (F) Total cell lysates were Western blotted for Skp2 and Cdk4 (loading control). (G) Total cell lysates were Western blotted 
for Rb; the hyper- and hypophosphorylated forms are shown by the top and bottom arrows, respectively. (H) ChiP was performed using anti-E2F1 
or control IgG, and the results were quantiﬁ  ed by QPCR. The level of immunoprecipitated Skp2 promoter is plotted relative to the input (×10
−3). 
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  Interestingly, GABP can cooperate with E2F1 to regulate the 
transcription of target genes (Izumi et al., 2000). 
We generated luciferase constructs with the wild-type 
mouse Skp2 promoter, including one with a mutation in the con-
served E2F site (Fig. 1 B), and transiently transfected them into 
MEFs. Chromatin immuno  precipitation (ChIP) performed with 
amplicons specifi  c for the transfected genes showed that E2F1 
bound to the transfected wild-type mouse Skp2 promoter but not 
to the transfected promoter with the E2F site mutation (Fig. 
1 C). Moreover, mutation of the single E2F site completely 
blocked the activity of a Skp2 promoter–luciferase construct 
in serum-stimulated or E7-  expressing MEFs (Fig. 1 D).
Skp2 mRNA levels fl  uctuate during cell cycle progression 
(Zhang et al., 1995). We found that Skp2 mRNA and protein 
expression are low in G0, gradually increase in early G1 phase, 
and further increase  15 h after mitogenic stimulation (Fig. 1, 
E and F, respectively). This second, late G1/S phase induction of 
Skp2 coincided with the hyperphosphorylation of Rb (Fig. 1 G). 
Moreover, this late G1/S phase induction of Skp2 mRNA closely 
matched the time-dependent increase in cyclin E1 mRNA (12–18 h; 
Fig. 1 E), a prototypic E2F1-regulated gene (DeGregori et al., 
1995). ChIP was then used to examine the time-dependent 
binding of endogenous E2F1 to the mouse Skp2 promoter 
(Fig. 1 H). Indeed, the binding of endogenous E2F1 to the con-
served site on the endogenous Skp2 promoter increased in late 
G1/S phase. Thus, the mid-to-late G1 phase induction of Skp2 
(12–18 h after mitogen stimulation) is regulated by E2F activity.
Others (Zhang and Wang, 2006) have reported that the 
  human Skp2 promoter contains three E2F-like sequences, one of 
which is the human homologue of the mouse E2F site reported 
in this paper (Fig. 1 B). However, these investigators concluded 
that a distinct, nonconserved E2F site (TTGCGCGCG) accounted 
for E2F-stimulated luciferase activity of the human Skp2 pro-
moter. Although we cannot exclude the possibility that the human 
promoter relies on this nonconserved E2F site, it is curious that 
a consensus E2F site (CGCGCAAA) did not contribute to E2F-
stimulated luciferase activity or interact with E2F in electropho-
retic mobility shift assays in Zhang and Wang (2006). We also 
note that the amplicon used to show binding of E2F1 to this 
nonconserved site in the human promoter includes the con-
served E2F site described in this report.
A Skp2 autoinduction loop 
in the G1/S transition
Our identifi  cation of a conserved E2F site in the mouse Skp2 
gene allowed us to assemble Rb-E2F, Skp2, p27, and cyclin E–
Cdk2 into a self-amplifying loop (Fig. 2 A). In this loop, the 
stimulatory effect of E2F on Skp2 gene expression would feed 
back to sustain Rb inactivation, E2F release, and further induc-
tion of the Skp2 gene in late G1 phase. Thus, this model predicts 
that Skp2 should induce itself and that this autoinduction should 
be detected as increased mRNA. Moreover, the autoinduction of 
Skp2 should occur in serum-deprived cells, because the loop is 
self-amplifying and does not require the presence of mitogens.
To test this model, we infected serum-free cultures of 
MEFs with an adenovirus encoding human Skp2 (Ad-hSkp2) 
and used a species-specifi  c Skp2 primer probe set with quantitative 
real-time RT-PCR (QPCR) to detect the induction of mouse Skp2 
mRNA. Ectopic expression of human Skp2 induced endog  -
enous mouse Skp2 mRNA, as well as other known E2F target 
genes (cyclins E1 and A; Fig. 2 B and Fig. S1, A and B, avail-
able at http://www.jcb.org/cgi/content/full/jcb.200703034/DC1). 
Induction of mouse Skp2 mRNA and down-regulation of p27 
by Ad-hSkp2 were seen when the serum-starved MEF were 
expressing ectopic Skp2 at near normal levels (compare FCS to 
60 MOI Ad-hSkp2; Fig. S2) and when the infection was per-
formed during or after the serum-starvation period (Fig. S3). 
Conversely, inhibition of the loop by RNAi-mediated knock down 
of Skp2 reduced serum-stimulated Skp2 promoter activation 
(Fig. 2 C). As expected, this Skp2 requirement was lost after 
pocket protein inactivation with E7 (Fig. 2 C).
The loop shown in Fig. 2 A predicts that the autoinduction 
of Skp2 requires Cdk activity, and we indeed found that the in-
duction of endogenous Skp2 mRNA seen in response to ectopic 
Ad-hSkp2 in serum-starved MEFs was blocked by the Cdk in-
hibitor roscovitine (Fig. 3 A). Conversely, expression of cyclin E 
induced Skp2 mRNA and protein in serum-deprived MEFs 
(Fig. 3 B and Fig. S1 C). The autoinduction of Skp2 mRNA 
was effi  ciently inhibited in serum-deprived MEFs when transit 
through the loop was precluded by knockin of a Skp2-resistant 
p27 mutant, p27
T187A (Fig. 3 C).
A characteristic of positive feedback loops is that they 
yield “all-or-nothing” responses. Indeed, we observed stepwise 
increases in cyclin E1 gene induction (Fig. 3 D, top) and S phase 
entry (Fig. 3 D, middle) upon infection of serum- starved MEFs 
with increasing MOIs of Ad-hSkp2. The maximal responses 
Figure 2.  A feedback loop for Skp2 autoinduction. (A) A positive feed-
back loop that perpetuates Skp2 induction and Rb inactivation in the ab-
sence of exogenous mitogens. (B) RNA from serum-starved MEFs infected 
with Ad-LacZ or Ad-hSkp2 was analyzed by QPCR; the levels of Skp2, 
cyclin E1, and cyclin A mRNAs are plotted relative to their levels in the 
Ad-LacZ–infected cells. (C) Skp2 promoter activity in cells transfected with 
an irrelevant control siRNA or Skp2 siRNA, infected with Ad-LacZ or Ad-E7, 
and stimulated with 10% FCS for 24 h. The Western blot shows representa-
tive Skp2 and actin levels in MEFs transfected with control (Co) siRNA or 
Skp2 (S2) siRNA, serum starved, and stimulated with 10% FCS for 24 h. 
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occurred with near-normal levels of Skp2 protein and were clearly 
distinguishable from the gradual increase in Skp2 expression 
(Fig. 3 D, bottom). The induction of endogenous Skp2 mRNA and 
degradation of p27 also occurred in a stepwise fashion (Fig. S2, avail-
able at http://www.jcb.org/cgi/content/full/jcb.200703034/DC1). 
Marti et al. (1999) have reported that Skp2 degrades E2F1 in 
G2/M phase cells. However, Ad-hSkp2 did not decrease E2F1 
levels in serum-deprived MEFs (Fig. 3 D, bottom), which is con-
sistent with the fact that Skp2 stimulates S phase entry under these 
conditions. Collectively with Marti et al. (1999), this result sug-
gests that Skp2 may switch from a positive to a negative regulator 
of E2F activity as cells progress from G1/S to G2/M. Ad-hCyclin E 
also had no effect on E2F1 levels (unpublished data).
Skp2 autoinduction and restriction 
point control
The Skp2 autoinduction loop has the potential to regulate S phase 
entry because it can perpetuate the down-regulation of p27 
and, thereby, the activation of cyclin E–Cdk2, phosphorylation 
of Rb and release of E2Fs. However, Malek et al. (2001), using 
knockin of p27
T187A, reported that Skp2-mediated p27 degrada-
tion is not required for S phase entry in serum-stimulated MEFs. 
Because the Skp2 autoinduction loop can function in mitogen-
deprived cells (Fig. 2), we reasoned that these results could be 
reconciled if Skp2-mediated p27 degradation was essential only 
for the transition to mitogen independence, also called the re-
striction point (Blagosklonny and Pardee, 2002). We therefore 
used p27
T187A MEFs to interrupt the Skp2 autoinduction loop 
and look for consequences on the restriction point.
To measure passage through the restriction point, serum-
starved p27
T187A or wild-type MEFs were stimulated with 10% 
FCS for selected times. The serum was removed, and the cells 
were incubated with serum-free medium and BrdU. S phase 
entry in the wild-type MEFs required mitogens for the fi  rst 10 h 
after serum stimulation and then quickly became mitogen inde-
pendent (Fig. 4 A, WT). This rapid transition to mitogen inde-
pendence was defective in primary p27
T187A MEFs; these cells 
did not become mitogen independent until 16 h (Fig. 4 A, T187A). 
Importantly, this defect in restriction-point control was not 
caused by a general decrease in the rate of cycling because, as 
previously reported (Malek et al., 2001), the kinetics of S phase 
entry were nearly identical when wild-type and p27
T187A MEFs 
were continuously exposed to mitogens (Fig. 4 B). Thus, Skp2-
dependent degradation of p27, and probably the Skp2 auto-
induction loop, regulates progression through the restriction point. 
A positive feedback loop should accelerate the transition to 
  mitogen independence, and we indeed fi  nd that the rate of pro-
gression through the restriction point is decreased when transit 
through the loop is blocked in p27
T187A MEFs (Fig. 4 A).
Previous papers have proposed that passage through the re-
striction point is regulated by a positive feedback loop comprised 
of cyclin E and Rb-E2F (Dou et al., 1993; Blagosklonny and 
Pardee, 2002). In this model, cyclin E activation of Cdk2 would 
stimulate Rb phosphorylation and E2F-dependent transcription 
of the cyclin E1 gene, thereby furthering Rb inactivation and 
cyclin E1 induction. However, we reasoned that the repeated 
autoinduction of cyclin E might also require Skp2-mediated 
p27 degradation to allow for the activation of cyclin E–Cdk2. 
Figure 3.  Characteristics of the Skp2 autoinduction loop. 
(A) Serum-starved MEFs infected with Ad-LacZ or Ad-
hSkp2 were pretreated for 3 h with DMSO or 20 μM 
roscovitine and then incubated for 24 h with BrdU. Skp2 
mRNA was quantiﬁ  ed by QPCR and plotted relative to its 
level in the Ad-LacZ–infected cells. BrdU incorporation 
analysis showed that roscovitine inhibited the effect of 
Ad-hSkp2 on S phase entry by >90%. (B) Serum-starved 
MEFs were infected with Ad-LacZ or Ad–hCyclin E. Skp2 
mRNA was quantiﬁ  ed by QPCR and plotted relative to 
its level in the Ad-LacZ–infected cells. (C) Skp2 mRNA in 
serum-starved wild-type (WT) and p27
T187A (T187A) MEFs 
infected with Ad-LacZ or Ad-hSkp2 was determined by 
QPCR and plotted relative to its level in Ad-LacZ–infected 
wild-type cells. (D) Serum-starved MEFs were infected with 
increasing (3.7–100) MOI Ad-hSkp2 or 100 MOI Ad-LacZ. 
Lysates were examined for cyclin E1 mRNA (top), BrdU 
  incorporation (middle), or protein expression (bottom) of 
Skp2, E2F1, and actin (loading control). Cyclin E1 mRNA 
levels were determined by QPCR and plotted relative to its 
level in the Ad-LacZ–infected cells. The Western blot in-
cludes a lysate from serum-starved MEFs treated for 24 h 
with 10% FCS to show the level of endogenous Skp2. The 
Western blots were derived from the same experiment. 
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Based on this reasoning, the cyclin E autoinduction loop would 
be within, rather than separate from, the Skp2 autoinduction 
loop. To test this notion, we used a species-specifi  c QPCR 
primer-probe set to mouse cyclin E1 mRNA to compare the 
effi  ciency of cyclin E autoinduction in wild-type and p27
T187A 
MEFs infected with an adenovirus encoding human cyclin E. 
Indeed, we found that the autoinduction of cyclin E1 mRNA 
was barely detected in p27
T187A MEFs (Fig. 4 C). This result 
strongly suggests that the major effects of cyclin E and Rb/E2F 
in restriction point control depend on their inclusion in the Skp2 
autoinduction loop.
Others have reported that APC/C
Cdh1 stimulates Skp2 pro-
tein degradation (Bashir et al., 2004; Wei et al., 2004), and that 
APC/C
Cdh1 activity is inhibited by the E2F-dependent induction 
of Emi1 (Hsu et al., 2002). We therefore envision that the in-
activation of pocket proteins and release of E2F controls the 
  restriction point through the coordinated effects of the tran-
scriptionally based Skp2 autoinduction loop described in this 
report and the posttranscriptionally based APC/C
Cdh1 pathway. 
Both of these effects would converge to increase the expres-
sion of Skp2 and degradation of p27. We note that p27
T187A 
MEFs are not completely restrictionless, indicating that other 
Skp2 targets may also contribute to restriction point control. 
Alternatively, an independent positive feedback loop, perhaps 
in which Rb-E2F induces cyclin D1 (Ohtani et al., 1995), may 
cooperate with the loop described in this report.
In addition to its effect on cell cycle progression, the Skp2 
autoinduction loop may contribute to cell cycle exit associated 
with pocket protein activation. Others have reported that Rb and 
p107 regulate p27 levels posttranscriptionally by acting as a 
scaffold for Skp2 and Cdh1 and thereby facilitating APC/C
Cdh1-
dependent Skp2 proteolysis (Ji et al., 2004; Rodier et al., 2005; 
Binne et al., 2007). Interestingly, this rapid posttranscription 
down-regulation of Skp2 should inhibit the Skp2 autoinduction 
loop, which would in turn prevent Skp2 gene transcription and 
thereby enforce the quiescent state. Thus, coordinated transcrip-
tional and posttranscriptional pocket protein effects on Skp2 lev-
els may contribute to both the transition to mitogen independence 
and the G1 phase arrest that follows mitogen withdrawal.
Skp2 knock down or p27 overexpression inhibit S phase 
entry in serum-stimulated cells (Polyak et al., 1994; Toyoshima 
and Hunter, 1994; Zhang et al., 1995), whereas S phase entry is 
nearly normal in p27
T187A MEFs (Malek et al., 2001; Fig. 4 B) 
cultured under similar conditions. These results imply that 
p27
T187A MEFs (which have gone through mouse development 
in the absence of wild-type p27) may have acquired a compen-
satory mechanism that bypasses the need for Skp2-mediated 
p27 degradation in mitogen-bathed cells. In contrast, the restric-
tion point defect is clearly seen in p27
T187A MEFs, emphasizing 
that the role of Skp2-mediated p27 degradation in the transition 
to mitogen independence is essential.
Skp2 is dispensable in E7-expressing 
cells: implications for Skp2 in cellular 
transformation
The results in Fig. 4 show that autoinduction of Skp2 is linked 
to effi  cient progression through the restriction point. However, 
this loop might become dispensable if Rb is inactivated by 
  oncogenes during cellular transformation. To explore this possibil-
ity, we inactivated pocket proteins by ectopic expression of E7, 
knocked down Skp2 with siRNA, and determined the consequence 
of reduced Skp2 expression on S phase entry in serum-deprived 
MEFs (conditions where Skp2- mediated p27 degradation is 
required for the feedback loop and S phase entry; Figs. 2–4). 
Interestingly, S phase entry was not inhibited by knock down of 
Skp2 (Fig. 5, A and B), and a distinct Skp2 siRNA gave similar 
results (not depicted). We also found that Skp2 siRNA inhibited 
S phase entry in serum-stimulated MEFs, but even this Skp2 
requirement was lost upon expression of E7 (Fig. 5, C and D).
Elevated Skp2 expression is observed in cancers and has 
been considered a causative factor due, in part, to its effects on 
p27 (Gstaiger et al., 2001; Kamata et al., 2005; Zheng et al., 2005). 
Figure 4.  The Skp2 autoinduction loop controls the restriction point. 
(A) Restriction point analysis in wild-type (WT) and p27
T187A (T187A) 
MEFs. Results are plotted relative to the BrdU incorporation observed at the 
last time point (34 and 39% for wild type and p27
T187A MEFs, respectively). 
(B) S phase entry in wild-type and p27
T187A MEFs continuously incubated 
with 10% FCS and BrdU. Results are plotted relative to the BrdU incorpo-
ration observed at the last time point (44 and 48% for wild-type and 
p27
T187A MEFs, respectively). (C) Serum-starved wild-type (WT) and 
p27
T187A (T187A) MEFs were infected with increasing (3.7–100) MOI of 
Ad–hCyclin E or 100 MOI Ad-LacZ (shown as 0 MOI Ad–hCyclin E). The 
level of mouse cyclin E1 mRNA was determined by QPCR (using a primer-
probe set that recognizes mouse, but not human, cyclin E1 mRNA) and 
plotted relative to its level in the Ad-LacZ–infected cells. Error bars show 
mean ± SD.JCB • VOLUME 178 • NUMBER 5 • 2007  746
However, our data indicate that high Skp2 expression may sim-
ply be a consequence of aberrant Rb inactivation and E2F re-
lease. Because many cancers constitutively activate upstream 
mitogenic signaling pathways that sustain Rb inactivation, the 
ability of Skp2 to sustain Rb inactivation through the feedback 
loop shown in Fig. 2 A may not be needed in cancer cells. 
Indeed, our results indicate that S phase entry induced by E7 is 
independent of Skp2. In fact, the notion that Skp2-mediated 
degradation of p27 may not be required for tumor development 
is supported by the fi  nding that the p27
T187A mutation does not 
delay tumorigenesis in mouse models of Ras-dependent lung 
and colon cancer (Timmerbeul et al., 2006).
Materials and methods
Cell culture
Spontaneously immortalized MEFs were maintained in DME (Invitrogen) 
with 5% FBS. For experimentation, near conﬂ  uent cells were serum starved 
in DME with 1 mg/ml heat-inactivated, fatty acid–free BSA (DME-BSA; 
Sigma-Aldrich) for 48 h, trypsinized, reseeded at subconﬂ  uence, and stim-
ulated largely as described previously (Welsh et al., 2001). Stimulated 
cells were washed once with cold PBS, scraped, collected by centrifugation, 
quick frozen, and stored at −80°C before analysis. S phase entry was de-
termined by incorporation of BrdU (Kothapalli et al., 2003). Primary MEFs 
from wild-type and p27
T187A knockin mice were maintained in 10% FCS 
and used at passages 2–5. To study progression through the restriction 
point, serum-starved wild-type and p27
T187A MEFs were replated at subcon-
ﬂ  uence in 35-mm dishes and stimulated with 10% FCS for selected times. 
The FCS-containing medium was removed, and the cells were washed 
once with a 50-mM glycine, 150-mM NaCl, pH 2.8, acid wash buffer and 
twice with cold DME and were then incubated in DME-BSA for a total incu-
bation of 17 h. BrdU was added to all of the plates, and the incubation 
continued for an additional 12 h before determining BrdU incorporation 
(relative to total DAPI-stained nuclei) by immunoﬂ  uorescence microscopy. 
BrdU results show mean ± SD from multiple ﬁ  elds of view.
Skp2 promoter–luciferase constructs and assays
A 1.9-kb fragment of the mouse Skp2 promoter (bases −1,253 to 263) was 
cloned by PCR from ICR Swiss mouse DNA (Promega), ligated into the KpnI 
and BglII sites of pGL3 basic (Promega), and conﬁ  rmed by DNA sequencing. 
Analysis of a 5′−Skp2 promoter–luciferase deletion series revealed that the 
minimal active promoter is from −362 to 263 (unpublished data); this con-
struct was used for the luciferase assays shown. Mutagenesis of the E2F site 
at +114–121 was performed using the QuikChange multi site-directed mu-
tagenesis kit (Stratagene) with the forward oligo (5′-G  G  G  G  A  T  C  A  C  T  C  T  A  A  G-
C  C  G  A  A  C  T  T  T  C  A  G  A  C  A  G  G  A  G  T  C  T  G  G  A  A  G  G  C  A  G  -3′) and the reverse oligo 
(5′-C  T  G  C  C  T  T  C  C  A  G  A  C  T  C  C  T  G  T  C  T  G  A  A  A  G  T  T  C  G  G  C  T  T A  G  A  G  T  G  A T  C  C  C  C  -3′).
MEFs ( 60% conﬂ  uent) in a six-well plate were transiently cotrans-
fected as described previously (Bottazzi et al., 1999), but using 1 μg 
Skp2-pGL3, 0.1 ng cytomegalovirus–Renilla luciferase, 4 μl Lipofectamine 
(Invitrogen), and 6 μl Plus reagent (Invitrogen) per well. For experiments 
using E7, the cells were cotransfected with 0.5 μg of the ﬁ  reﬂ  y luciferase 
vector driven by wild-type (S
wt) or E2F-mutated (S
Em) Skp2 promoter, 0.1 ng 
CMV–Renilla luciferase, and either 0.5 μg of E7 plasmid or empty vector. 
After a 24-h incubation in 10% FCS, the cells were collected in passive 
  lysis buffer, and luciferase activity was determined using the dual-luciferase 
reporter assay system (Promega). Measurements were performed in dupli-
cate and recorded as mean  SD. Skp2 luciferase activity was normalized 
to Renilla luciferase activity.
Transfections, infections, and RNAi
Unless noted otherwise in the ﬁ  gure legends, conﬂ  uent MEFs were infected 
with adenoviruses after a 12-h incubation in serum-free DME-BSA. The cells 
were infected overnight at 100 MOI using adenoviruses encoding GFP, 
Ad-LacZ, Ad-E7 (provided by J. Meinkoth, University of Pennsylvania, 
Philadelphia, PA), human cyclin E1 (Ad–hCyclin E; provided by J. Albrecht, 
University of Minnesota, Minneapolis, MN, and S. Reed, University of 
California, San Diego, San Diego, CA), or Ad-hSkp2 (provided by 
K.   Nakayama, Kyusu University, Fukuoka City, Fukuoka, Japan), and then 
  incubated in fresh serum-free medium to obtain a total serum-free medium 
incubation time of 48 h. For plasmid transfections, MEFs were transiently 
transfected as described previously (Welsh et al., 2001) using 5 μg pCDNA3.1 
(vector control), pCDNA3.1-based E7, or pcDNA3.1-based human E2F1. 
Transfected cells were incubated overnight in DME containing 10% FCS 
  before use or serum starvation for 24–36 h. Transfections of siRNAs were 
performed as described previously (Walker et al., 2006), except that 100 nM 
irrelevant (human E cadherin; G  A  G  U  G  A  A  U  U  U  U  G  A  A  G  A  U  U  G  tt) or mouse 
Skp2 (U  U  U  G  U  C  A  C  U  C  C  C  U  U  U  G  C  C  C  tt) siRNAs were used.
When adenoviral infection was combined with siRNA, near conﬂ  u-
ent MEFs were serum starved for 12 h, infected with either Ad-E7 or Ad-
LacZ, and incubated for 24 h in DME-BSA. The medium was removed, and 
the infected cells were transfected with the irrelevant control siRNA or Skp2 
siRNA. After an additional 24 h, the siRNA-containing medium was re-
placed with DME-BSA or 10% FCS DME with BrdU, and the incubation 
was continued for another 24 h. After a total of 84 h in serum-free medium, 
coverslips were collected for analysis of BrdU incorporation. In some ex-
periments, the siRNA transfection also contained 0.05 μg of the wild-type 
Skp2 promoter–luciferase and 0.05 ng of Renilla luciferase vectors.
QPCR
Collected cell pellets were lysed in 0.5–1 ml of TRIzol (Invitrogen) to extract 
total RNA. Real-time PCR for mouse Skp2 and Cdk4 were performed as 
previously described (Stewart et al., 2004). Controls (unpublished data) 
demonstrated that the mouse Skp2 primer probe set did not detect human 
Skp2 mRNA. Mouse cyclin E1 mRNA, mouse cyclin A mRNA, and 18S 
rRNA levels were determined using assay-on-demand primer probe sets 
Mm00432367_ml, Mm00438064_ml, and Hs99999901_s1 (Applied 
Biosystems), respectively. Skp2 and cyclin E1 mRNAs were normalized to 
Cdk4 mRNA or 18S rRNA, neither of which varied reproducibly in re-
sponse to any of the treatments used. Duplicate PCR reactions were run for 
each sample, and results are plotted as mean  SD. Results shown in the 
ﬁ  gures are typically representative of three independent experiments.
ChIP
ChIPs were performed as described previously (Klein et al., 2007) using 10
6 
MEFs per sample and 5 μg of either anti-E2F1 (C-20X; Santa Cruz Biotech-
nology, Inc.) or preimmune antibody control. One tenth of the ﬁ  nal immuno-
pre  cipitated DNA (5 μl) was analyzed by QPCR with SYBR green to quantify 
the amount of immunoprecipitated Skp2 promoter. Primer sequences for mouse 
Skp2 were 5′-T  G  G  T  G  A  T  G  G  A  A  C  G  T  T  G  C  T  A  G  T  -3′ (forward) and 5′-G  G  T  G-
T  C  C  A  C  T  G  A  T  T  C  A  G  G  A  -3′ ( reverse). ChIPs on MEFs transiently transfected 
with Skp2 promoter–luciferase constructs were performed as previously 
described (Klein et al., 2007) and analyzed by PCR using 5′-T  G  G  T  G  A  T  G-
G  A  A  C  G  T  T  G  C  T  A  G  T  -3′ (forward) and 5′-C  T  T  T  A  T  G  T  T  T  T  T  G  G  C  G  T  C  T  T  C  C  A  -3′ 
Figure 5.  Effect of Skp2 siRNA in E7-expressing cells. (A) Serum-starved 
MEFs infected with either Ad-E7 (E7) or Ad-LacZ (LZ) were transfected with 
an irrelevant control (Co) siRNA or Skp2 (S2) siRNA and incubated with 
BrdU for 24 h in serum-free medium to assess S phase entry. (B) The experi-
ment in A was repeated except that the collected cells were analyzed by 
Western blotting for Skp2 and actin (loading control). (C and D) The experi-
ments in A and B were repeated except that the 24-h incubation with BrdU 
was performed in the presence of 10% FCS. Error bars show mean  SD. MITOGEN-INDEPENDENT CELL CYCLE PROGRESSION • YUNG ET AL. 747
(reverse; encoding plasmid backbone sequence within the promoter–
  luciferase construct). The ampliﬁ  ed PCR product (300 bp) was detected on 
a 1.5% agarose gel.
Western blotting
Western blotting was performed as described previously (Welsh et al., 
2001) using 30–40 μg of total cellular protein and the following anti-
bodies: Skp2 (SKP2-2B12; Invitrogen), Cdk4 (C-22 [Santa Cruz Biotech-
nology, Inc.] or DCS-31 [Invitrogen]), p27 (clone 57; BD Biosciences), Rb 
(Mab1; Invitrogen), E2F1 (C-20; Santa Cruz Biotechnology, Inc.) cyclin E 
(M-20; Santa Cruz Biotechnology, Inc.), and actin (1616R and C-2; Santa 
Cruz Biotechnology, Inc.). The resolved proteins were detected using ECL 
(GE Healthcare). Autoradiographs were digitized by scanning, and ﬁ  gures 
were assembled using Photoshop (Adobe).
Online supplemental material
Fig. S1 complements the mRNA analysis in Figs. 2 B and 3 B to show that 
infection with Ad-hSkp2 or Ad–hCyclin E leads to protein expression of the 
E2F targets, cyclin A, cyclin E, and Skp2. Fig. S2 shows that near endog-
enous levels of Skp2 can initiate the Skp2 autoinduction loop. Fig. S3 
shows that Skp2 expression can initiate the Skp2 autoinduction loop even 
when cells are fully quiescent. Online supplemental material is available at 
http://www.jcb.org/cgi/content/full/jcb.200703034/DC1.
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